The case to infect volunteers with COVID-19 to accelerate vaccine testing | Nir Eyal

TL;DR

In this content, the author discusses the possibility of conducting challenge trials for COVID-19 vaccines, weighing the ethical considerations and discussing potential benefits and risks involved.

Transcript

please welcome near a all thank you very much Chris for the opportunity to present this and I'm really enjoying the discussion so far with thousands of people dying globally every day from coronavirus and thousands more condemned to death by its disruptions think about how much in life we could save by adopting testing methods for vaccines that are... Read More

Key Insights

• 🔬 Testing methods for vaccines can be accelerated to save lives and reduce the time to roll out.
• 🧪 Challenge trials, where participants are deliberately infected with the virus, could be a faster and more efficient method of testing vaccine efficacy.
• ⚖️ Ethical justification for challenge trials lies in minimizing risks to participants and the potential to save thousands of lives.
• 💉 Comparing risk levels in challenge trials to other medical procedures, such as kidney donation, shows that the risks can be tolerable.
• 🌍 The number of lives at stake due to the slow vaccine development process highlights the urgency for faster testing methods.
• 🚧 Balancing the ethics of action and inaction, challenge trials can potentially save hundreds of thousands of lives.
• 🤔 The complexity of ethical considerations in challenge trials includes selecting participants, ensuring informed consent, and minimizing risks.
• ⭐️ Participants in challenge trials should be recognized as heroes, and society should celebrate their courage and sacrifice.
• ❓ The risks in challenge trials can be assessed based on existing data on infection rates and outcomes in specific age groups.

Questions & Answers

Q: How can testing methods for vaccines be accelerated to save more lives?

The conventional way to test the efficacy of vaccines is time-consuming. It involves distributing the vaccine to one group and a control to another, then waiting for enough exposures to the virus to see differences in infection rates. However, a proposed method called challenge trials involves deliberately infecting everyone participating in the trial. This method can provide faster results and determine whether the vaccine offers greater protection than the control.

Q: What is the ethical justification for challenge trials with potential risks?

The level of risk in challenge trials can be justified ethically by comparing it to other medical practices. For example, kidney donation carries a risk of death in one in 3,000 cases, which is considered tolerable. In the case of challenge trials, if young individuals without preconditions are selected as participants, the risk of death from infection is estimated to be lower than in kidney donation cases (1 in 12,000). The potential thousands of lives saved from adopting accelerated testing methods make this risk-benefit balance acceptable from a population-level bioethical perspective.

Q: How are challenge trials different from traditional vaccine testing in terms of risk?

Challenge trials involve deliberately infecting participants with the virus, which increases the potential for unnecessary deaths. However, by carefully selecting younger individuals without preconditions and minimizing the risk further by excluding individuals with higher susceptibility to severe COVID-19 outcomes, the overall risk can be significantly reduced. While there is no guarantee of zero severe outcomes, the focus is on minimizing the risks and providing the best medical care available to trial participants.

Q: How do you ensure the participation of marginalized and vulnerable groups in challenge trials?

It is essential to address the inclusion of marginalized and vulnerable groups in challenge trials. While it is crucial to have highly educated participants who fully comprehend the risks, it is also important to avoid exploiting individuals participating solely for financial gain. Finding a balance includes focusing on populations that are likely to be infected but excluding the most marginalized individuals. The goal should be to provide these communities with a voice and ensure their representation in trials, ultimately leading to equitable access to tested vaccines.

Q: How can society change the narrative surrounding challenge trial participants?

Challenge trial volunteers who willingly put themselves at risk in the pursuit of advancing vaccine development should be celebrated and regarded as heroes. Similar to how astronauts or individuals who engage in noble acts are celebrated, challenge trial volunteers are courageous individuals with good intentions. Recognizing their bravery, intelligence, and leadership can help change the narrative and promote greater understanding of the importance of their role in saving lives.

Summary & Key Takeaways

• The speaker proposes adopting testing methods for vaccines that are accelerated in order to save lives from the coronavirus.

• They suggest using a challenge trial, where participants are deliberately infected with the virus to quickly see the results of the vaccine's efficacy.

• The speaker argues that the risk involved in the challenge trial can be justified ethically by minimizing the risk to participants and the potential benefits to a large number of people.